Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients

[1] Mattiuzzi C(2019)Current cancer epidemiology J Epidemiol Glob Health 9 217-22

[2] Lippi G(2017)The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA Nat Rev Urol 14 26-37

[3] Fleshner K(2020)Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT) Eur Urol 77 713-24

[4] Carlsson SV(2021)EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer Eur Urol 79 263-82

[5] Roobol MJ(2021)Obesity as a risk factor for prostate cancer mortality: a systematic review and dose-response meta-analysis of 280,199 patients Cancers (Basel) 13 4169-501

[6] Wilt TJ(2011)Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis Cancer Prev Res (Philos) 4 486-22

[7] Vo TN(2014)Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients Med Oncol 31 311-9

[8] Langsetmo L(2015)Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis World J Surg Oncol 13 2713-300

[9] Dahm P(2020)Effect of obesity on the prognosis and recurrence of prostate cancer after radical prostatectomy: a meta-analysis Transl Androl Urol 9 j4008-50

[10] Wheeler T(2017)AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both BMJ 358 n71-34

[1] Mattiuzzi C(2019)Current cancer epidemiology J Epidemiol Glob Health 9 217-22

[2] Lippi G(2017)The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA Nat Rev Urol 14 26-37

[3] Fleshner K(2020)Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT) Eur Urol 77 713-24

[4] Carlsson SV(2021)EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer Eur Urol 79 263-82

[5] Roobol MJ(2021)Obesity as a risk factor for prostate cancer mortality: a systematic review and dose-response meta-analysis of 280,199 patients Cancers (Basel) 13 4169-501

[6] Wilt TJ(2011)Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis Cancer Prev Res (Philos) 4 486-22

[7] Vo TN(2014)Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients Med Oncol 31 311-9

[8] Langsetmo L(2015)Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis World J Surg Oncol 13 2713-300

[9] Dahm P(2020)Effect of obesity on the prognosis and recurrence of prostate cancer after radical prostatectomy: a meta-analysis Transl Androl Urol 9 j4008-50

[10] Wheeler T(2017)AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both BMJ 358 n71-34